An Overview of the BR-002 Trial in Breast Cancer
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.
Clinical Pearls:
- This trial seeks to confirm that a local intervention does not change the outcome of a patient
- Participants of the trial will be randomized to ablation or standard treatment
- Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy​
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
